쿼드메디슨
4,090KRWMarket close of 10/27 (Tue)
Down -2.39%-100KRWMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)4,365KRWUp +6.72%
Preliminary · replaced once official KRX data for the same date is published
- Open
- 4,300
- High
- 4,300
- Low
- 4,030
- Day range
- Day range low 4,030 high 4,300, open 4,300, close 4,090, previous close 4,190
- Volume
- 3×10K shares
- 116.08 million KRW 0.48× the 20-session average
Market close of 10/27 (Tue)
Where it sits in the 1-year range
0%0% of the way up from the lowest close in 1 year (210 sessions) · -83.3% from the high
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsnot verifiedThe last four quarters are incomplete, so not verified
- Recent filingsnot verifiedOutside filing data coverage, so not verified
- Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
The other 2 are within the usual range
- Daily move-2.39%usual range
- Trading value0.5×usual range
See the full check report
Quarterly results · Q2 2026
- Operating income-2.4B KRW
- vs. year ago
- Turned to loss
- vs. prior quarter
- Still a loss
Quarterly operating income trend
As of the latest official close · 2026-10-27Valuation filing date · 2026-08-13Same sector · 제약
Down -2.22%· 88 of 168 stocks up, preferred shares excluded · trading value 553.0B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 삼성바이오로직스 | Close over the last 20 sessions +0.6% | Down -5.37% | 124.5B KRW |
| 셀트리온 | Close over the last 20 sessions +6.3% | Down -0.74% | 82.4B KRW |
| 지투지바이오 | Close over the last 20 sessions +22.2% | Down -13.38% | 46.9B KRW |
| 한미약품 | Close over the last 20 sessions -32.6% | Down -0.57% | 25.5B KRW |
| 에스티팜 | Close over the last 20 sessions -11.9% | Down -9.15% | 21.4B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 18 days
- Next data 10/29 (Thu) after 08:50
Related news
Tables, financials, investor flows and filing history are in the Detailed view.
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 82% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.